Literature DB >> 17482910

Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers.

Néviton M Castro1, Waldyr Rodrigues, Daniel M Freitas, André Muniz, Paulo Oliveira, Edgar M Carvalho.   

Abstract

OBJECTIVES: To describe the frequency of urologic manifestations in human T-cell lymphotropic virus type I (HTLV-I) seropositive individuals from Salvador and other cities in Bahia, Brazil, with or without clinical HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
METHODS: A total of 218 HTLV-I seropositive subjects referred from blood banks or neurologic clinics were admitted to the HTLV-I multidisciplinary outpatient clinic from January 2001 to April 2004. They were assessed using a standardized questionnaire to determine urinary complaints and quality of life. Neurologic impairment was established using the Expanded Disability Status Scale (EDSS). HAM/TSP was considered as an EDSS score of 2 or greater.
RESULTS: Nocturia (35.8%) was the most frequent finding, followed by incontinence (29.8%), urgency (25.2%), frequency (22.0%), and dysuria (15.6%). Differences were found between individuals with an EDSS score of 0 and those with an EDSS score greater than 0 but less than 2 regarding frequency, nocturia, urgency, urinary loss of any degree, and quality of life. Dysuria and great or total urinary loss were more frequent among those with severe HAM/TSP (EDSS score greater than 6).
CONCLUSIONS: Even HTLV-I subjects considered not to have HAM/TSP may have prominent urinary findings already present. Urologic manifestations, including nocturia and urinary loss, might be early manifestations of neurologic disease in those with HTLV-I.

Entities:  

Mesh:

Year:  2007        PMID: 17482910     DOI: 10.1016/j.urology.2007.01.052

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection.

Authors:  Cristina Toledo-Cornell; Silvane Santos; Gloria Orge; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2013-09-11       Impact factor: 2.327

2.  Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection.

Authors:  Silvane Braga Santos; Paulo Oliveira; Tania Luna; Anselmo Souza; Márcia Nascimento; Isadora Siqueira; Davi Tanajura; André Luiz Muniz; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

3.  Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.

Authors:  Davi Tanajura; Néviton Castro; Paulo Oliveira; Abraão Neto; André Muniz; Natália B Carvalho; Glória Orge; Silvane Santos; Marshall J Glesby; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2015-03-27       Impact factor: 9.079

4.  Impact of depression on quality of life in people living with human T cell lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil.

Authors:  Ana Verena Galvão-Castro; Ney Boa-Sorte; Ramon Almeida Kruschewsky; Maria Fernanda Rios Grassi; Bernardo Galvão-Castro
Journal:  Qual Life Res       Date:  2011-11-23       Impact factor: 4.147

5.  Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder.

Authors:  Paulo Oliveira; Néviton M Castro; André L Muniz; Davi Tanajura; Julio C Brandão; Aurélia F Porto; Edgar M Carvalho
Journal:  Urology       Date:  2010-02-26       Impact factor: 2.649

6.  Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.

Authors:  Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby
Journal:  J Clin Virol       Date:  2011-03-08       Impact factor: 3.168

Review 7.  Retroviruses and amyotrophic lateral sclerosis.

Authors:  Tariq Alfahad; Avindra Nath
Journal:  Antiviral Res       Date:  2013-05-23       Impact factor: 5.970

8.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

Review 9.  [HTLV-1-associated myelopathy/tropical spastic paraparesis: a differential diagnosis in multiple sclerosis].

Authors:  A Liesz; S Hähnel; K Korn; M Esiri; W Hacke; B Wildemann
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

10.  Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.

Authors:  Tomohiro Matsuo; Tatsufumi Nakamura; Katsuya Sato; Yasuyoshi Miyata; Hideki Sakai
Journal:  IJU Case Rep       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.